Regen Biopharma Inc (RGBPP) financial statements (2021 and earlier)
Company profile
| Business Address |
4700 SPRING ST #304 LA MESA, CA 91942 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | 9/30/2014 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 8 | 270 | 39 | ||||
| Cash and cash equivalents | 8 | 270 | 39 | ||||
| Receivables | 8 | 107 | 1 | 0 | |||
| Prepaid expense | 8 | 34 | 10 | ||||
| Other undisclosed current assets | 19 | 67 | 12 | 10 | |||
| Total current assets: | 43 | 478 | 62 | 11 | |||
| Noncurrent Assets | |||||||
| Other undisclosed noncurrent assets | 166 | 466 | 158 | ||||
| Total noncurrent assets: | 166 | 466 | 158 | ||||
| TOTAL ASSETS: | 209 | 944 | 220 | 11 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 656 | 591 | 10 | 72 | 12 | ||
| Accounts payable | 81 | 496 | 26 | 3 | |||
| Accrued liabilities | 10 | 10 | |||||
| Employee-related liabilities | 4 | 1 | 36 | 8 | |||
| Other undisclosed accounts payable and accrued liabilities | 571 | 94 | |||||
| Debt | 0 | 50 | 6 | ||||
| Due to related parties | 0 | 111 | 143 | 20 | 90 | ||
| Other undisclosed current liabilities | 8,017 | 5,161 | 226 | 32 | |||
| Total current liabilities: | 8,674 | 5,863 | 203 | 318 | 140 | ||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 656 | 332 | |||||
| Long-term debt, excluding current maturities | 656 | 332 | |||||
| Other undisclosed noncurrent liabilities | 1 | ||||||
| Total noncurrent liabilities: | 657 | 332 | |||||
| Total liabilities: | 9,331 | 6,196 | 203 | 318 | 140 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | (9,122) | (5,251) | (97) | (130) | |||
| Preferred stock | 6 | ||||||
| Common stock | 18 | 14 | 11 | 5 | |||
| Additional paid in capital | 7,518 | 6,643 | 11,664 | 485 | |||
| Accumulated other comprehensive income (loss) | 53 | 88 | (34) | ||||
| Accumulated deficit | (17,457) | (12,742) | (12,474) | (1,279) | |||
| Other additional capital | 729 | 729 | 729 | 659 | |||
| Other undisclosed stockholders' equity attributable to parent | 18 | 17 | 0 | ||||
| Other undisclosed stockholders' equity | 0 | ||||||
| Total stockholders' equity: | (9,122) | (5,251) | (97) | (130) | |||
| TOTAL LIABILITIES AND EQUITY: | 209 | 944 | 203 | 220 | 11 | ||
Income statement (P&L) ($ in thousands)
| 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | 9/30/2014 | ||
|---|---|---|---|---|---|---|
| Revenues | 100 | 110 | 192 | |||
| Other income | 51 | ✕ | ||||
| Cost of revenue | (408) | (649) | (575) | (159) | ||
| Gross profit: | (308) | (539) | (383) | (159) | ||
| Operating expenses | (1,118) | (1,972) | (1,597) | (548) | ||
| Other operating expense, net (Other Expenses) | (14) | |||||
| Other undisclosed operating income | 14 | |||||
| Operating loss: | (1,426) | (2,511) | (1,979) | (706) | ||
| Nonoperating income (Debt Instrument, Convertible, Beneficial Conversion Feature) | 50 | |||||
| Interest and debt expense | (363) | (99) | (22) | (2) | ||
| Net income (loss): | (1,789) | (2,610) | 50 | (2,001) | (709) | |
| Other undisclosed net loss attributable to parent | (2,926) | (3,229) | (48) | |||
| Net income (loss) available to common stockholders, diluted: | (4,715) | (5,839) | 50 | (2,001) | (756) | |
Comprehensive Income ($ in thousands)
| 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | 9/30/2014 | ||
|---|---|---|---|---|---|---|
| Net income (loss): | (1,789) | (2,610) | 50 | (2,001) | (709) | |
| Other comprehensive income (loss) | (35) | 168 | (34) | |||
| Comprehensive income (loss): | (1,824) | (2,442) | 50 | (2,035) | (709) | |
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (2,926) | (3,229) | (9,194) | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (4,750) | (5,671) | 50 | (11,229) | (709) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.